About: Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Chauffert Bruno, Blay Jean-Yves, Le Cesne Axel, Chevreau Christine, Bompas Emmanuelle, Bertucci François, Cupissol Didier, Saada-Bouzid Esma, Duffaud Florence, Feuvret Loic, Bay Jacques Olivier, Vauleon Elodie, Noel Georges, Penel Nicolas, Mir Olivier. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). European Journal of Cancer, Elsevier, 2017, 79, pp.119 - 128. ⟨10.1016/j.ejca.2017.03.037⟩
  • Lebellec Loïc, Chauffert Bruno, Blay Jean-Yves, Le Cesne Axel, Chevreau Christine, Bompas Emmanuelle, Bertucci François, Cupissol Didier, Fabbro Michel, Saada-Bouzid Esma, Duffaud Florence, Feuvret Loic, Bonneville-Levard Alice, Bay Jacques Olivier, Vauleon Elodie, Vinceneux Armelle, Noel Georges, Penel Nicolas, Mir Olivier. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). European Journal of Cancer, Elsevier, 2017, 79, pp.119 - 128. ⟨10.1016/j.ejca.2017.03.037⟩
  • Chauffert Bruno, Blay Jean-Yves, Le Cesne Axel, Chevreau Christine, Bompas Emmanuelle, Bertucci François, Cupissol Didier, Saada-Bouzid Esma, Duffaud Florence, Feuvret Loic, Bay Jacques Olivier, Vauleon Elodie, Noel Georges, Penel Nicolas, Mir Olivier . Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors . A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF) . European Journal of Cancer, 2017, 79, pp.119 - 128 . ⟨10.1016/j.ejca.2017.03.037⟩
Title
  • Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
dc:date
  • 2017
Digital Object Identifier (DOI)
  • 10.1016/j.ejca.2017.03.037
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software